Target early-stage bios Small biotech focus and seed-stage funding indicate potential long sales cycles but high-value partnerships for device integration, requiring targeted outreach to medical device manufacturers, hospital systems, and research labs exploring extracorporeal CO2 removal.

CO2 removal opportunity Core product revolves around extracorporeal carbon dioxide removal for hypercarbic respiratory failure, suggesting sales opportunities with critical care departments, pulmonology units, and respiratory therapy teams in hospitals treating COPD, cystic fibrosis, and acute trauma cases.

Clinical trial potential Recent fundraising and progress toward clinical testing signal readiness for partnerships with contract research organizations, trial sites, and regulatory consultants to accelerate development and potential first-in-human studies.

Strategic financing signals Seed financing and external advisory engagement imply openness to collaboration and co-development deals, as well as potential for grant funding or strategic investments from larger pharmaceutical or medical device firms.

Low current scale Revenue under one million and a small team suggest focusing on collaborative opportunities, pilot programs, and integration trials rather than large-scale deployments, with emphasis on demonstrating proof of value and return on investment.